iSign Solutions (ISGN) 10-Q 15 May 15 2015 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	3 Months Ended
	Mar. 31, 2015	15-May-15	Jun. 30, 2014
Document and Entity Information [Abstract]
Entity Registrant Name	Communication Intelligence Corp
Entity Central Index Key	727634
Document Type	10-Q
Document Period End Date	31-Mar-15
Amendment Flag	FALSE
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q1
Current Fiscal Year End Date	-19
Entity Well-known Seasoned Issuer	Yes
EntityVoluntaryFilers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		234,307,542
Entity Public Float			$3,811,679

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Current assets:
Cash and cash equivalents	$1,289	$775
Accounts receivable, net of allowance of $40 at March 31, 2015 and $22 at December 31, 2014	254	122
Prepaid expenses and other current assets	104	80
Total current assets	1,647	977
Property and equipment, net	13	11
Patents, net	846	933
Other assets	29	29
Total assets	2,535	1,950
Current liabilities:
Accounts payable	432	328
Accrued compensation	282	293
Other accrued liabilities	377	338
Deferred revenue	433	257
Total current liabilities	1,524	1,216
Deferred revenue long-term	595	700
Deferred rent	30	41
Derivative liability	2	18
Other accrued and long-term liabilities	28	28
Total liabilities	2,179	2,003
Commitments and Contingencies
Stockholders' deficit
Common Stock, $0.01 par value; 2,000,000 shares authorized; 234,308 issued and outstanding at March 31, 2015 December 31, 2014	2,407	2,407
Treasury shares, 6,500 shares at March 31, 2015 and December 31, 2014 respectively	-325	-325
Additional paid in capital	94,844	94,995
Accumulated deficit	-124,202	-123,199
Accumulated other comprehensive loss	-14	-14
Total CIC stockholder's equity (deficit)	892	483
Non-Controlling interest	-536	-536
Total stockholders' equity (deficit)	356	-53
Total liabilities and shareholders' equity	2,535	1,950
Series A-1 Preferred Stock [Member]
Stockholders' deficit
Preferred stock by class of stock	892	875
Total stockholders' equity (deficit)	892	875
Series B Preferred Stock [Member]
Stockholders' deficit
Preferred stock by class of stock	10,683	10,381
Total stockholders' equity (deficit)	10,683	10,381
Series C Preferred Stock [Member]
Stockholders' deficit
Preferred stock by class of stock	5,675	5,553
Total stockholders' equity (deficit)	5,675	5,553
Series D-1 Preferred Stock [Member]
Stockholders' deficit
Preferred stock by class of stock	6,119	5,139
Total stockholders' equity (deficit)	6,119	5,139
Series D-2 Preferred Stock [Member]
Stockholders' deficit
Preferred stock by class of stock	4,813	4,671
Total stockholders' equity (deficit)	$4,813	$4,671

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Current assets:
Accounts receivable, allowance	$40,000	$22,000
Stockholders' deficit
Common Stock, par value	$0.01	$0.01
Common Stock, shares authorized	2,000,000,000	2,000,000,000
Common Stock, shares issued	234,308,000	232,560,000
Common Stock, shares outstanding	234,308,000	232,560,000
Treasury shares	6,500,000	6,500,000
Series A-1 Preferred Stock [Member]
Stockholders' deficit
Preferred stock, par value	$0.01	$0.01
Preferred stock, shares authorized	2,000,000	2,000,000
Preferred stock, shares issued	892,000	875,000
Preferred stock, shares outstanding	892,000	875,000
Preferred stock, liquidation preference	892,000
Series B Preferred Stock [Member]
Stockholders' deficit
Preferred stock, par value	$0.01	$0.01
Preferred stock, shares authorized	14,000,000	14,000,000
Preferred stock, shares issued	12,554,000	12,251,000
Preferred stock, shares outstanding	12,554,000	12,251,000
Preferred stock, liquidation preference	18,830,000
Series C Preferred Stock [Member]
Stockholders' deficit
Preferred stock, par value	$0.01	$0.01
Preferred stock, shares authorized	9,000,000	9,000,000
Preferred stock, shares issued	5,097,000	4,975,000
Preferred stock, shares outstanding	5,097,000	4,975,000
Preferred stock, liquidation preference	7,646,000
Series D-1 Preferred Stock [Member]
Stockholders' deficit
Preferred stock, par value	$0.01	$0.01
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	7,178,000	5,800,000
Preferred stock, shares outstanding	7,178,000	5,800,000
Preferred stock, liquidation preference	7,178,000
Series D-2 Preferred Stock [Member]
Stockholders' deficit
Preferred stock, par value	$0.01	$0.01
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	5,921,000	5,720,000
Preferred stock, shares outstanding	5,921,000	5,720,000
Preferred stock, liquidation preference	$5,921,000

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Operations (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Revenue:
Product	$230	$128
Maintenance	216	173
Total revenues	446	301
Cost of sales:
Product	111	4
Maintenance	12	54
Research and development	522	540
Sales and marketing expense	298	308
General and administrative expense	521	463
Total operating costs and expenses	1,464	1,369
Loss from operations	-1,018	-1,068
Other expense, net	-1	2
Gain on derivative liability	16	5
Net loss	-1,003	-1,061
Accretion of beneficial conversion feature, preferred shares:
Related party	-458	-73
Other	-69	-301
Preferred stock dividends:
Related party	-354	-328
Other	-376	-293
Income tax
Net loss before non-controlling interest	-2,260	-2,056
Net loss attributable to non-controlling interest
Net loss attributable to common stockholders	($2,260)	($2,056)
Basic and diluted loss per common share	($0.01)	($0.01)
Weighted average common shares outstanding, basic and diluted	234,308	232,560

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Cash Flows (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Cash flows from operating activities:
Net loss	($1,003)	($1,061)
Adjustments to reconcile net loss to net cash used for operating activities:
Depreciation and amortization	89	92
Stock-based employee compensation	213	92
Gain on derivative liability	-16	-5
Changes in operating assets and liabilities:
Accounts receivable, net	-132	132
Prepaid expenses and other assets	-24	-1
Accounts payable	104	-142
Accrued Compensation	-11	-4
Other accrued liabilities	28	-3
Deferred revenue	71	-33
Net cash used in operating activities	-681	-933
Cash flows from investing activities:
Acquisition of property and equipment	-5	-4
Net cash used in investing activities	-5	-4
Cash flows from financing activities:
Proceeds from issuance of Series D preferred Stock, net of issuance costs of $33 and $51 respectively	1,200	1,139
Net cash provided by financing activities	1,200	1,139
Effect of exchange rate changes on cash and cash equivalents
Net decrease in cash and cash equivalents	514	202
Cash and cash equivalents at beginning of period	775	945
Cash and cash equivalents at end of period	1,289	1,147
Supplemental disclosure of cash flow information:
Interest paid	1
Income tax paid
Non-cash financing and investing transactions:
Dividends on preferred shares	730	621
Accretion of beneficial conversion feature on issuance of convertible Preferred Stock	498	306
Accretion of beneficial conversion feature on issuance of Preferred Stock dividends	$29	$68

Condensed_Consolidated_Stateme2

Condensed Consolidated Statements of Comprehensive Loss (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Comprehensive income:
Net loss	($1,003)	($1,061)
Foreign currency translation adjustment
Total comprehensive loss	($1,003)	($1,061)

Nature_of_business_basis_of_pr

Nature of business, basis of presentation and summary of significant accounting policies	3 Months Ended
	Mar. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of business, basis of presentation and summary of significant accounting policies	1. Nature of business and summary of significant accounting policies
	Nature of Business
	Communication Intelligence Corporation and its subsidiary (the "Company" or "CIC") is a leading provider of digital transaction management (DTM) software enabling fully digital (paperless) business processes. The Company's solutions encompass a wide array of functionality and services, including electronic signatures, biometric authentication and simple-to-complex workflow management. These solutions are available across virtually all enterprise, desktop and mobile environments as a seamlessly integrated platform for both ad-hoc and fully automated transactions. The Company's platform can be deployed both on-premise and as a cloud-based service, with the ability to easily transition between deployment models. To date, the Company primarily has delivered its solutions to channel partners and end-user customers in the financial services industry. The Company's products include SignatureOne® Ceremony™ Server, the iSign® suite of products and services, including iSign® Enterprise and iSign® Console™, and Sign-it® programs.
	Basis of Presentation
	The financial information contained herein should be read in conjunction with the Company's consolidated audited financial statements and notes thereto included in its Annual Report on Form 10-K for the year ended December 31, 2014.
	The accompanying unaudited condensed consolidated financial statements of the Company have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America ("GAAP") for complete consolidated financial statements. In the opinion of management, the unaudited condensed consolidated financial statements included in this quarterly report reflect all adjustments (consisting only of normal recurring adjustments) that the Company considers necessary for a fair presentation of its financial position at the dates presented and the Company's results of operations and cash flows for the periods presented. The Company's interim results are not necessarily indicative of the results to be expected for the entire year.
	Going Concern
	The accompanying unaudited condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern. The Company has incurred significant cumulative losses since its inception and, at March 31, 2015 the Company's accumulated deficit was $124,202. The Company has primarily met its working capital needs through the sale of debt and equity securities. As of March 31, 2015, the Company's cash balance was $1,289. These factors raise substantial doubt about the Company's ability to continue as a going concern.
	There can be no assurance that the Company will be successful in securing adequate capital resources to fund planned operations or that any additional funds will be available to the Company when needed, or if available, will be available on favorable terms or in amounts required by the Company. If the Company is unable to obtain adequate capital resources to fund operations, it may be required to delay, scale back or eliminate some or all of its operations, which may have a material adverse effect on the Company's business, results of operations and ability to operate as a going concern. The unaudited condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.
	Accounting Changes and Recent Accounting Pronouncements
	Accounting Standards Issued But Not Yet Adopted
	Accounting standards that have been issued or proposed by the FASB or other standards-setting bodies are not expected to have a material impact on the Company's financial position, results of operations and cash flows.

Concentrations

Concentrations	3 Months Ended
	Mar. 31, 2015
Risks and Uncertainties [Abstract]
Concentration Risk Disclosure [Text Block]	2. Concentrations
	The following table summarizes accounts receivable and revenue concentrations:
		Accounts Receivable		Total Revenuefor
		As of March 31,		the three months
				ended March 31,
		2015	2014	2015	2014
	Customer #1	35%	-	27%	-
	Customer #2	28%	32%	15%	12%
	Customer #3	-	-	-	12%
	Customer #4	-	26%	-	-
	Customer #5	-	18%	-	22%
	Total concentration	63%	76%	42%	46%

Patents

Patents	3 Months Ended
	Mar. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Patents	3. Patents
	The Company performs an intangible asset impairment analysis at least annually or whenever circumstances or events indicate such assets might be impaired. The Company would recognize an impairment charge in the event the net book value of such assets exceeded the future undiscounted cash flows attributable to such assets.
	Management completed an analysis of the Company's patents as of December 31, 2014. Based on that analysis, the Company concluded that no impairment of the carrying value of the patents existed. The Company believes that no events or circumstances changed during the three months ended March 31, 2015 that would impact this conclusion.
	Amortization of patent costs was $87 for the three months ended March 31, 2015 and $89 for the three months ended March 31, 2014, respectively.
	Intangible Assets
	The following table summarizes intangible assets
	Amortizable intangible assets:	31-Mar-15		31-Dec-14
		Carrying	Accumulated	Carrying	Accumulative
		Amount	Amortization	Amount	Amortization
	Patents	$	$	$	$
		6,745	-5,899	6,745	-5,812

Net_loss_per_share

Net loss per share	3 Months Ended
	Mar. 31, 2015
Net loss per share [Abstract]
Net loss per share	4. Net loss per share
	The Company calculates basic net loss per share based on the weighted average number of shares outstanding, and when applicable, diluted income per share, which is based on the weighted average number of shares and potential dilutive shares outstanding.
	The following table lists shares and warrants that were excluded from the calculation of dilutive earnings per share as the exercise of such options and warrants and the conversion of such preferred shares would be anti-dilutive:
		For the three Months Ended
		31-Mar-15	31-Mar-14
	Stock options	107,645	72,037
	Warrants	230,012	94,240
	Preferred shares as if converted
	Series A-1 Preferred Stock	6,375	7,513
	Series B Preferred Stock	289,722	17,065
	Series C Preferred Stock	226,555	205,294
	Series D-1 Preferred Stock	319,033	191,189
	Series D-2 Preferred Stock	118,428	106,069

Equity

Equity	3 Months Ended
	Mar. 31, 2015
Stockholders' Equity [Abstract]
Stockholders' Equity	5. Equity
	Stock-based compensation expense is based on the estimated grant date fair value of the portion of stock-based payment awards that are ultimately expected to vest during the period. The grant date fair value of stock-based awards to employees and directors is calculated using the Black Scholes Merton valuation model.
	Forfeitures of stock-based payment awards are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The estimated average forfeiture rate for the three months ended March 31, 2015 and 2014 was approximately 7.57% and 9.76%, respectively, based on historical data.
	Valuation and Expense Information:
	The weighted-average fair value of stock-based compensation is based on the Black Scholes Merton valuation model. Forfeitures are estimated and it is assumed no dividends will be declared. The estimated fair value of stock-based compensation awards to employees is amortized over the vesting period of the options. The fair value calculations are based on the following assumptions:
		Three Months Ended	Three Months Ended
		31-Mar-15	31-Mar-14
	Risk free interest rate	0.04% - 3.73%	0.04% - 4.92%
	Expected term (years)	3.26 - 7.00	3.33 - 6.21
	Expected volatility	91.99% - 198.38%	91.99% - 198.38%
	Expected dividends	None	None
	The Company granted 35,633 stock options during the three months ended March 31, 2015 at a weighted average exercise price of $0.0225 per share. No stock options were exercised during the three month period ended March 31, 2015.
	The Company granted 2,500 stock options during the three months ended March 31, 2014 at a weighted average exercise price of $0.027 per share. No stock options were exercised during the month period ended March 31, 2014.
	The following table summarizes the allocation of stock-based compensation expense related to stock option grants for the three months ended March 31:
		2015	2014
	Research and development	$	$
		65	27
	Sales and marketing	52	12
	General and administrative	80	48
	Director	16	5
	Total stock-based compensation	$	$
		213	92
	A summary of option activity under the Company's plans as of March 31, 2015 and 2014 is as follows:
	Options	2015				2014
		Shares	Weighted	Weighted	Aggregate	Shares	Weighted	Weighted	Aggregate
			Average	Average	Intrinsic		Average	Average	Intrinsic
			Exercise	Remaining	Value		Exercise	Remaining	Value
			Price	Contractual			Price	Contractual
				Term				Term
	Outstanding at January 1	72,012	$			69,537	$
			0.04				0.05
	Granted	35,633	$			2,500	$		$
			0.02				0.03		7
	Exercised	-	$			-	$
			-				-
	Forfeited or expired	-	$			-	$
			-				-
	Outstanding at March 31	107,645	$	4.87		72,037	$	4.85	$
			0.04				0.05		7
	Vested and expected to vest at March 31	104,018	$	4.82	$	65,007	$	4.41	$
			0.04		-		0.05		7
	Exercisable at March 31	59,733	$	3.67		48,445	$	5.05	$
			0.05				0.05		-
	The following table summarizes significant ranges of outstanding and exercisable options as of March 31, 2015:
	Range of Exercise Prices	Options Outstanding			Options Exercisable
		Number	Weighted	Weighted	Number	Weighted
		Outstanding	Average	Average	Outstanding	Average
			Remaining	Exercise		Exercise
			Contractual	Price		Price
			Term (in years)
	$ 0.02 - $0.50	107,645	4.87	$	59,733	$
				0.04		0.05
	A summary of the status of the Company's non-vested shares as of March 31, 2015 is as follows:
	Non-vested Shares	Shares	Weighted
			Average
			Grant-Date
			Fair Value
	Non-vested at January 1, 2015	14,954	$
			0.04
	Granted	35,633	$
			0.02
	Exercised	-	$
			-
	Forfeited	-	$
-
Vested	-2,675	$
		0.04
Non-vested at March 31, 2015	47,912	$
		0.03
As of March 31, 2015, there was $592 of total unrecognized compensation expense related to non-vested stock-based compensation arrangements granted under the plans. The unrecognized compensation expense is expected to be realized over a weighted average period of 2.95 years.
Preferred Stock
Information with respect to the classes of Preferred Stock as of March 31, 2015 is as follows:
Class of	Annual	Annual	Liquidation	Conversion	Total	Common
Preferred	Dividend	Dividend	Preference	Price	Preferred	Shares to be
Stock		Payable, in			Shares	issued if
		Cash or In			Outstanding	Fully Converted
		Kind
Series A-1	8%	Quarterly in	$	$	892	6,375
		Arrears	1	0.14
Series B	10%	Quarterly in	$	$	12,554	289,722
		Arrears	1.5	0.0433
Series C		Quarterly in	$	$	5,097	226,555
		Arrears	1.5	0.0225
Series D-1	10%	Quarterly in	$	$	7,178	319,033
		Arrears	1	0.0225
Series D-2	10%	Quarterly in	$	$	5,921	118,428
		Arrears	1	0.05
Information with respect to dividends issued on the Company's Preferred stock for the period ended March 31 is as follows:
	March 31,		March 31,
	2015	2014	2015	2014
	Dividends		Beneficial Conversion
			Feature Related to
			dividends
	$	$	$	$
	17	20	-	-
Series B	302	274	-	-
Series C	123	111	13	37
Series D-1	145	93	16	31
Series D-2	143	123	-	-
Total	$	$	$	$
	730	621	29	68
Series D Preferred Stock
On February 7, 2014, the Company sold for $733 in cash, net of a $47 administrative fee paid in cash to SG Phoenix and a nonrelated third party, 520 Shares of Series D-1 preferred Stock and 260 shares of Series D-2 Preferred Stock. The investors received one hundred percent (100%) warrant coverage. These warrants are immediately exercisable and expire December 31, 2016. The warrants are exercisable in whole or in part and contain a cashless exercise provision.
On March 6, 2014, the Company sold for $406 in cash, net of $4 in administrative fees paid in cash to an unrelated third party, 273 Shares of Series D-1 preferred Stock and 137 shares of Series D-2 Preferred Stock. The investors received one hundred percent (100%) warrant coverage. These warrants are immediately exercisable and expire December 31, 2016. The warrants are exercisable in whole or in part and contain a cashless exercise provision.
SG Phoenix received warrants to purchase 3,000 shares of Common stock, and two unrelated parties received warrants to purchase an aggregate of 1,600 shares of Common Stock in payment of administrative and finder's fees associated with the financings, in addition to the cash payments discussed above. These warrants are immediately exercisable and expire three (3) years from the date of issuance. The warrants are exercisable in whole or in part and contain a cashless exercise provision.
On March 24, 2015, the Company sold for $1,200 in cash, net of $33 in administrative fees paid in cash to SG Phoenix, 1,233 Shares of Series D-1 preferred Stock. The investors received 27,400 warrants, immediately exercisable into Common Stock of the Company at $0.0225 per share. The warrants expire March 23, 2018. The Company ascribed a value of $366 to the warrants using the Black Scholes Merton pricing model. See the warrant table below for more detail. The warrants are exercisable in whole or in part and contain a cashless exercise provision.
Warrants
On February 23, 2015, the Company and Venture Champion Asia Limited, an affiliate of IGC Global Limited, mutually agreed to terminate the $2,000 Credit Agreement signed in May 2014. At the time of the termination of the Credit Agreement, no amount was owed by the Company under the Credit Agreement, and contemporaneously with the termination of the Credit Agreement, the 10,909 warrants were likewise terminated.
A summary of the warrant activity is as follows:
	31-Mar-15		31-Dec-14
	Warrants	Weighted	Warrants	Weighted
		Average		Average
		Exercise Price		Exercise Price
Outstanding at beginning of period	213,521	$	77,155	$
		0.0289		0.0289
Issued	27,400	$	21,418	$
		0.0225		0.0225
Expired/Canceled	-10,909	$	-4,333	$
		-		0.0225
Outstanding at end of period	230,012	$	94,240	$
		0.0277		0.0289
Exercisable at end of period	230,012	$	94,240	$
		0.0277		0.0289
A summary of the status of the warrants outstanding and exercisable as of March 31, 2015 is as follows:
Number of Warrants	Weighted Average	Weighted Average
	Remaining Life	Exercise Price per
		share
27,400	3	$
		0.0225
193,968	1.77	$
		0.0275
8,644	0.28	$
		0.05
230,012	1.87	$
		0.0277

Nature_of_business_basis_of_pr1

Nature of business, basis of presentation and summary of significant accounting policies (Policies)	3 Months Ended
	Mar. 31, 2015
Summary of Significant Accounting Policies
Basis of presentation	Basis of Presentation
	The financial information contained herein should be read in conjunction with the Company's consolidated audited financial statements and notes thereto included in its Annual Report on Form 10-K for the year ended December 31, 2014.
	The accompanying unaudited condensed consolidated financial statements of the Company have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America ("GAAP") for complete consolidated financial statements. In the opinion of management, the unaudited condensed consolidated financial statements included in this quarterly report reflect all adjustments (consisting only of normal recurring adjustments) that the Company considers necessary for a fair presentation of its financial position at the dates presented and the Company's results of operations and cash flows for the periods presented. The Company's interim results are not necessarily indicative of the results to be expected for the entire year.
Going concern and management plans	Going Concern
	The accompanying unaudited condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern. The Company has incurred significant cumulative losses since its inception and, at March 31, 2015 the Company's accumulated deficit was $124,202. The Company has primarily met its working capital needs through the sale of debt and equity securities. As of March 31, 2015, the Company's cash balance was $1,289. These factors raise substantial doubt about the Company's ability to continue as a going concern.
	There can be no assurance that the Company will be successful in securing adequate capital resources to fund planned operations or that any additional funds will be available to the Company when needed, or if available, will be available on favorable terms or in amounts required by the Company. If the Company is unable to obtain adequate capital resources to fund operations, it may be required to delay, scale back or eliminate some or all of its operations, which may have a material adverse effect on the Company's business, results of operations and ability to operate as a going concern. The unaudited condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.
Recently issued accounting pronouncement	Accounting Changes and Recent Accounting Pronouncements
	Accounting Standards Issued But Not Yet Adopted
	Accounting standards that have been issued or proposed by the FASB or other standards-setting bodies are not expected to have a material impact on the Company's financial position, results of operations and cash flows.
Patents	The Company performs an intangible asset impairment analysis at least annually or whenever circumstances or events indicate such assets might be impaired. The Company would recognize an impairment charge in the event the net book value of such assets exceeded the future undiscounted cash flows attributable to such assets.
Net loss per share	The Company calculates basic net loss per share based on the weighted average number of shares outstanding, and when applicable, diluted income per share, which is based on the weighted average number of shares and potential dilutive shares outstanding.
Share-based payment	Stock-based compensation expense is based on the estimated grant date fair value of the portion of stock-based payment awards that are ultimately expected to vest during the period. The grant date fair value of stock-based awards to employees and directors is calculated using the Black Scholes Merton valuation model.
	Forfeitures of stock-based payment awards are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.

Concentration_Tables

Concentration (Tables)	3 Months Ended
	Mar. 31, 2015
Risks and Uncertainties [Abstract]
Schedule of accounts receivable and revenue concentration	The following table summarizes accounts receivable and revenue concentrations:
		Accounts Receivable		Total Revenuefor
		As of March 31,		the three months
				ended March 31,
		2015	2014	2015	2014
	Customer #1	35%	-	27%	-
	Customer #2	28%	32%	15%	12%
	Customer #3	-	-	-	12%
	Customer #4	-	26%	-	-
	Customer #5	-	18%	-	22%
	Total concentration	63%	76%	42%	46%

Patents_Tables

Patents (Tables)	3 Months Ended
	Mar. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Summary of Intangible Assets	Intangible Assets
	The following table summarizes intangible assets
	Amortizable intangible assets:	31-Mar-15		31-Dec-14
		Carrying	Accumulated	Carrying	Accumulative
		Amount	Amortization	Amount	Amortization
	Patents	$	$	$	$
		6,745	-5,899	6,745	-5,812

Net_loss_per_share_Tables

Net loss per share (Tables)	3 Months Ended
	Mar. 31, 2015
Net loss per share [Abstract]
Schedule of Antidilutive Securities Excluded from Calculation of Earnings Per Share	The following table lists shares and warrants that were excluded from the calculation of dilutive earnings per share as the exercise of such options and warrants and the conversion of such preferred shares would be anti-dilutive:
		For the three Months Ended
		31-Mar-15	31-Mar-14
	Stock options	107,645	72,037
	Warrants	230,012	94,240
	Preferred shares as if converted
	Series A-1 Preferred Stock	6,375	7,513
	Series B Preferred Stock	289,722	17,065
	Series C Preferred Stock	226,555	205,294
	Series D-1 Preferred Stock	319,033	191,189
	Series D-2 Preferred Stock	118,428	106,069

Equity_Tables

Equity (Tables)	3 Months Ended
	Mar. 31, 2015
Stockholders' Equity [Abstract]
Key assumptions for fair value calculation, stock options	The fair value calculations are based on the following assumptions:
		Three Months Ended	Three Months Ended
		31-Mar-15	31-Mar-14
	Risk free interest rate	0.04% - 3.73%	0.04% - 4.92%
	Expected term (years)	3.26 - 7.00	3.33 - 6.21
	Expected volatility	91.99% - 198.38%	91.99% - 198.38%
	Expected dividends	None	None
Allocation of stock-based compensation expense related to stock option grants	The following table summarizes the allocation of stock-based compensation expense related to stock option grants for the three months ended March 31:
		2015	2014
	Research and development	$	$
		65	27
	Sales and marketing	52	12
	General and administrative	80	48
	Director	16	5
	Total stock-based compensation	$	$
		213	92
Summary of option activity	A summary of option activity under the Company's plans as of March 31, 2015 and 2014 is as follows:
	Options	2015				2014
		Shares	Weighted	Weighted	Aggregate	Shares	Weighted	Weighted	Aggregate
			Average	Average	Intrinsic		Average	Average	Intrinsic
			Exercise	Remaining	Value		Exercise	Remaining	Value
			Price	Contractual			Price	Contractual
				Term				Term
	Outstanding at January 1	72,012	$			69,537	$
			0.04				0.05
	Granted	35,633	$			2,500	$		$
			0.02				0.03		7
	Exercised	-	$			-	$
			-				-
	Forfeited or expired	-	$			-	$
			-				-
	Outstanding at March 31	107,645	$	4.87		72,037	$	4.85	$
			0.04				0.05		7
	Vested and expected to vest at March 31	104,018	$	4.82	$	65,007	$	4.41	$
			0.04		-		0.05		7
	Exercisable at March 31	59,733	$	3.67		48,445	$	5.05	$
			0.05				0.05		-
Summary of the significant ranges of outstanding and exercisable options	The following table summarizes significant ranges of outstanding and exercisable options as of March 31, 2015:
	Range of Exercise Prices	Options Outstanding			Options Exercisable
		Number	Weighted	Weighted	Number	Weighted
		Outstanding	Average	Average	Outstanding	Average
			Remaining	Exercise		Exercise
			Contractual	Price		Price
			Term (in years)
	$ 0.02 - $0.50	107,645	4.87	$	59,733	$
				0.04		0.05
Summary of the status of the Company's non-vested shares	A summary of the status of the Company's non-vested shares as of March 31, 2015 is as follows:
	Non-vested Shares	Shares	Weighted
			Average
			Grant-Date
			Fair Value
	Non-vested at January 1, 2015	14,954	$
			0.04
	Granted	35,633	$
			0.02
	Exercised	-	$
			-
	Forfeited	-	$
			-
	Vested	-2,675	$
			0.04
	Non-vested at March 31, 2015	47,912	$
			0.03
Information with respect to the classes of Preferred Stock	Information with respect to the classes of Preferred Stock as of March 31, 2015 is as follows:
	Class of	Annual	Annual	Liquidation	Conversion	Total	Common
	Preferred	Dividend	Dividend	Preference	Price	Preferred	Shares to be
	Stock		Payable, in			Shares	issued if
			Cash or In			Outstanding	Fully Converted
			Kind
	Series A-1	8%	Quarterly in	$	$	892	6,375
			Arrears	1	0.14
	Series B	10%	Quarterly in	$	$	12,554	289,722
			Arrears	1.5	0.0433
	Series C		Quarterly in	$	$	5,097	226,555
			Arrears	1.5	0.0225
	Series D-1	10%	Quarterly in	$	$	7,178	319,033
			Arrears	1	0.0225
	Series D-2	10%	Quarterly in	$	$	5,921	118,428
			Arrears	1	0.05
Information with respect to dividends issued on the Company's preferred stock	Information with respect to dividends issued on the Company's Preferred stock for the period ended March 31 is as follows:
		March 31,		March 31,
		2015	2014	2015	2014
		Dividends		Beneficial Conversion
				Feature Related to
				dividends
		$	$	$	$
		17	20	-	-
	Series B	302	274	-	-
	Series C	123	111	13	37
	Series D-1	145	93	16	31
	Series D-2	143	123	-	-
	Total	$	$	$	$
		730	621	29	68
Summary of the warrants issued	A summary of the warrant activity is as follows:
		31-Mar-15		31-Dec-14
		Warrants	Weighted	Warrants	Weighted
			Average		Average
			Exercise Price		Exercise Price
	Outstanding at beginning of period	213,521	$	77,155	$
			0.0289		0.0289
	Issued	27,400	$	21,418	$
			0.0225		0.0225
	Expired/Canceled	-10,909	$	-4,333	$
			-		0.0225
	Outstanding at end of period	230,012	$	94,240	$
			0.0277		0.0289
	Exercisable at end of period	230,012	$	94,240	$
			0.0277		0.0289
Status of the warrants outstanding	A summary of the status of the warrants outstanding and exercisable as of March 31, 2015 is as follows:
	Number of Warrants	Weighted Average	Weighted Average
		Remaining Life	Exercise Price per
			share
	27,400	3	$
			0.0225
	193,968	1.77	$
			0.0275
	8,644	0.28	$
			0.05
	230,012	1.87	$
			0.0277

Nature_of_business_basis_of_pr2

Nature of business, basis of presentation and summary of significant accounting policies (Details Textual) (USD $)	Mar. 31, 2015	Dec. 31, 2014	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash and Cash Equivalents, at Carrying Value	$1,289	$775	$1,147	$945
Accumulated deficit	($124,202)	($123,199)

Concentrations_Details

Concentrations (Details)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Accounts Receivable [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	63.00%	76.00%
Accounts Receivable [Member] | Customer One [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	35.00%
Accounts Receivable [Member] | Customer Two[Member]
Concentration Risk [Line Items]
Concentration risk, percentage	28.00%	32.00%
Accounts Receivable [Member] | Customer Four [Member]
Concentration Risk [Line Items]
Concentration risk, percentage		26.00%
Accounts Receivable [Member] | Customer Five [Member]
Concentration Risk [Line Items]
Concentration risk, percentage		18.00%
Sales Revenue, Services, Net [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	42.00%	46.00%
Sales Revenue, Services, Net [Member] | Customer One [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	27.00%
Sales Revenue, Services, Net [Member] | Customer Two[Member]
Concentration Risk [Line Items]
Concentration risk, percentage	15.00%	12.00%
Sales Revenue, Services, Net [Member] | Customer Three [Member]
Concentration Risk [Line Items]
Concentration risk, percentage		12.00%
Sales Revenue, Services, Net [Member] | Customer Five [Member]
Concentration Risk [Line Items]
Concentration risk, percentage		22.00%

Patents_Details

Patents (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Amortizable intangible assets
Finite-lived intangible assets, gross	$6,745	$6,745
Finite-Lived intangible assets, accumulated amortization	($5,899)	($5,812)

Patents_Details_Textual

Patents (Details Textual) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
Patent amortization expense	$87	$89
Patents impairment	$0	$0

Net_loss_per_share_Details

Net loss per share (Details)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Series A Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, shares	6,375	7,513
Series B Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, shares	289,722	17,065
Series C Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, shares	226,555	205,294
Series D One Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, shares	319,033	191,189
Series D Two Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, shares	118,428	106,069
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, shares	107,645	72,037
Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, shares	230,012	94,240

Equity_Details

Equity (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Employee Service Share-based Compensation, Aggregate Disclosures [Abstract]
Risk-free interest rate, minimum	0.04%	0.04%
Risk-free interest rate, maximum	3.73%	4.92%
Expected volatility, minimum	91.99%	91.99%
Expected volatility, maximum	198.38%	198.38%
Expected dividend yield	$0	$0
Minimum [Member]
Fair value assumptions, stock options
Expected life	3 years 3 months 4 days	3 years 3 months 29 days
Maximum [Member]
Fair value assumptions, stock options
Expected life	7 years	6 years 10 months 17 days

Equity_Details_1

Equity (Details 1) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	$213	$92
Research and Development Expense [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	65	27
Selling and Marketing Expense [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	52	12
General and Administrative Expense [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	80	48
Director Expense [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	$16	$5

Equity_Details_2

Equity (Details 2) (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Summary of stock options outstanding
Stock Options Outstanding, Beginning Balance	72,012	69,537
Stock Options, Granted	35,633	2,500
Stock Options, Exercised
Stock Options, Forfeited, or expired
Stock Options Outstanding, Ending Balance	107,645	72,037
Stock Options, Vested and expected to vest at ending balance	104,018	65,007
Options exercisable	59,733	48,445
Weighted Average Exercise Price, Beginning Period	$0.04	$0.05
Weighted Average Exercise Price, Granted	$0.02	$0.03
Weighted Average Exercise Price, Exercised
Weighted Average Exercise Price, Forfeited, or expired
Weighted Average Exercise Price, Ending Period	$0.04	$0.05
Weighted Average Exercise Price, Vested and expected to vest at ending balance	$0.04	$0.05
Weighted Average Exercise Price, Exercisable at ending balance	$0.05	$0.05
Weighted Average Remaining Contractual Term, ending balance	4 years 10 months 13 days	4 years 10 months 1 day
Weighted Average Remaining Contractual Term, vested and expected to vest at ending balance	4 years 9 months 26 days	4 years 4 months 28 days
Weighted Average Remaining Contractual Term, excercisable at ending balance	3 years 8 months 1 day	5 years 0 months 2 days
Aggregate Intrinsic Value, Beginning Balance
Aggregate Intrinsic Value, Granted		7
Aggregate Intrinsic Value, Exercised
Aggregate Intrinsic Value, Forfeited or expired
Aggregate Intrinsic Value, Ending Balance		7
Aggregate Intrinsic Value, Vested and expected to vest at ending balance		7
Aggregate Intrinsic Value, Exercisable at ending balance

Equity_Details_3

Equity (Details 3) (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, End of Period [Abstract]
Outstanding Options, Weighted Average Exercise Price	$0.00	$0.00
Range One [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price Range, Lower Range Limit	$0.02
Exercise Price Range, Upper Range Limit	$0.50
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, End of Period [Abstract]
Number of Outstanding Options	107,645
Outstanding Options, Weighted Average Remaining Contractual Term	4 years 10 months 1 day
Outstanding Options, Weighted Average Exercise Price	$0.04
Exercise Price Range, Number of Exercisable Options	59,733
Exercisable Options, Weighted Average Exercise Price	$0.05

Equity_Details_4

Equity (Details 4) (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2015
Equity Instruments, Options, Nonvested Shares Roll-Forward
Non-vested shares, Beginning Balance	14,954
Non-vested shares, Granted	35,633
Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested Excercised In Period
Non-vested shares, Forfeited, or expired
Non-vested shares, vested	-2,675
Stock Options Outstanding, Ending Balance	47,912
Weighted Average Grant Date Fair Value, Options Nonvested at beginning of period	$0.04
Weighted Average Grant Date Fair Value, Options nonvested, grants in period	$0.02
Weighted Average Grant Date Fair Value Options Nonvested Excercised In Period
Weighted Average Grant Date Fair Value, Options nonvested, forfeited in period
Weighted Average Grant Date Fair Value, Options nonvested, vested in period	$0.04
Weighted Average Grant Date Fair Value, Options nonvested at end of period	$0.03

Equity_Details_5

Equity (Details 5) (USD $)	3 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Annual Dividend	0.00%
Series A Preferred Stock [Member]
Annual Dividend	8.00%
Annual Dividend Payable, in Cash or In Kind	Quarterly in Arrears
Liquidation preference	$1
Conversion price	$0.14
Total Preferred Shares Outstanding	892,000	875,000
Common Shares to be Issued if Fully Converted	6,375,000
Series B Preferred Stock [Member]
Annual Dividend	10.00%
Annual Dividend Payable, in Cash or In Kind	Quarterly in Arrears
Liquidation preference	1.5
Conversion price	$0.04
Total Preferred Shares Outstanding	12,554,000	12,251,000
Common Shares to be Issued if Fully Converted	289,722,000
Series C Preferred Stock [Member]
Annual Dividend	10.00%
Annual Dividend Payable, in Cash or In Kind	Quarterly in Arrears
Liquidation preference	1.5
Conversion price	$0.02
Total Preferred Shares Outstanding	5,097,000	4,975,000
Common Shares to be Issued if Fully Converted	226,555,000
Series D One Preferred Stock [Member]
Annual Dividend	10.00%
Annual Dividend Payable, in Cash or In Kind	Quarterly in Arrears
Liquidation preference	1
Conversion price	$0.02
Total Preferred Shares Outstanding	7,178,000	5,800,000
Common Shares to be Issued if Fully Converted	319,033,000
Series D Two Preferred Stock [Member]
Annual Dividend	10.00%
Annual Dividend Payable, in Cash or In Kind	Quarterly in Arrears
Liquidation preference	$1
Conversion price	$0.05
Total Preferred Shares Outstanding	5,921,000	5,720,000
Common Shares to be Issued if Fully Converted	118,428,000

Equity_Details_6

Equity (Details 6) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Dividends Net of Beneficial Conversion Feature	$730	$621
Accretion of beneficial conversion feature related to dividends	29	68
Series A Preferred Stock [Member]
Dividends Net of Beneficial Conversion Feature	17	20
Accretion of beneficial conversion feature related to dividends
Series B Preferred Stock [Member]
Dividends Net of Beneficial Conversion Feature	302	274
Accretion of beneficial conversion feature related to dividends
Series C Preferred Stock [Member]
Dividends Net of Beneficial Conversion Feature	123	111
Accretion of beneficial conversion feature related to dividends	13	37
Series D One Preferred Stock [Member]
Dividends Net of Beneficial Conversion Feature	145	93
Accretion of beneficial conversion feature related to dividends	16	31
Series D Two Preferred Stock [Member]
Dividends Net of Beneficial Conversion Feature	143	123
Accretion of beneficial conversion feature related to dividends

Equity_Details_7

Equity (Details 7) (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Class Of Warrant Or Right Number Of Warrants Or Rights Roll Forward
Number of Warrants Outstanding at beginning of period	213,521	77,155
Number of warrants issued	27,400	21,418
Number Of Warrants Or Rights Exercised
Number Of Warrants Or Rights Expired	-10,909	-4,333
Number of Warrants Outstanding at end of period	230,012	94,240
Number of Warrants Or Rights Exercisable at end of period	230,012	94,240
Excercise Price of Warrants Outstanding at beginning of period	$0.03	$0.03
Exercise Price Of Warrants Issued	$0.02	$0.02
Exercise Price Of Warrants Exercised
Exercise Price Of Warrants Expired	$0.02	$0.02
Excercise Price of Warrants Outstanding at end of period	$0.03	$0.03
Exercise Price Of WarrantsExercisable at end of period	$0.03	$0.03

Equity_Details_8

Equity (Details 8) (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2015	Dec. 31, 2014	Mar. 31, 2014	Dec. 31, 2013
Class of Warrant or Right [Line Items]
Number of Warrants Outstanding and Excercisable	230,012	213,521	94,240	77,155
Weighted Average Remaining Life Of Warrants Or Rights	1 year 10 months 13 days
Warrants Weighted Average Exercise Price	$0.03	$0.03	$0.03	$0.03
Warrants Group One [Member]
Class of Warrant or Right [Line Items]
Number of Warrants Outstanding and Excercisable	27,400
Weighted Average Remaining Life Of Warrants Or Rights	3 years
Warrants Weighted Average Exercise Price	$0.02
Warrants Group Two [Member]
Class of Warrant or Right [Line Items]
Number of Warrants Outstanding and Excercisable	193,968
Weighted Average Remaining Life Of Warrants Or Rights	1 year 9 months 7 days
Warrants Weighted Average Exercise Price	$0.03
Warrants Group Three [Member]
Class of Warrant or Right [Line Items]
Number of Warrants Outstanding and Excercisable	8,644
Weighted Average Remaining Life Of Warrants Or Rights	0 years 3 months 11 days
Warrants Weighted Average Exercise Price	$0.05

Equity_Details_Textual

Equity (Details Textual) (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Share-based Arrangements with Employees and Nonemployees [Abstract]
Estimated average forfeiture rate	7.57%	9.76%
Stock Options, Granted	35,633	2,500
Outstanding Options, Weighted Average Exercise Price	$0.00	$0.00
Stock Options, Exercised
Total unrecognized compensation expense related to non-vested share-based compensation arrangements granted under the plans	$592
Unrecognized compensation expense amortization period	2 years 11 months 12 days

Equity_Details_Textual_1

Equity (Details Textual 1) (USD $)	3 Months Ended	1 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2015	Feb. 28, 2014	Dec. 31, 2014	Dec. 31, 2013
Subsidiary, Sale of Stock [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$0.03	0.0289	$0.03		$0.03	$0.03
Venture Champion Asia Limited [Member]
Subsidiary, Sale of Stock [Line Items]
Credit Agreement origination date	6-May-14
Line of Credit Facility, Current Borrowing Capacity	$2,000		$2,000
Line of Credit Facility, Fair Value of Amount Outstanding	0		0
Credit Agreement expiration date	23-Feb-15
Warrants Issued to SG Phoenix [Member]
Subsidiary, Sale of Stock [Line Items]
Fair Value Assumptions, Expected Term		3 years
Number of common shares callable by warrants		3,000
Warrants Issued to Unrelated Parties [Member]
Subsidiary, Sale of Stock [Line Items]
Fair Value Assumptions, Expected Term		3 years
Number of common shares callable by warrants		1,600
Series D Preferred Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Proceeds from sale of stock, net		406	1,200	733
Administrative fee		4	33	47
Warrant coverage, maximum percentage		100.00%		100.00%
Fair Value Assumptions, Expected Term			3 years
Class of Warrant or Right, Exercise Price of Warrants or Rights	$0.00		$0.00
Warrants, expiration date		31-Dec-16	31-Mar-18	31-Dec-16
Number of common shares callable by warrants	27,400		27,400
Warrants And Rights Issued Fair Value Initial	$366		$366
Series D One Preferred Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Number of shares sold in private placement		273	1,233	520
Series D Two Preferred Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Number of shares sold in private placement		137		260
Note Warrant [Member] | Venture Champion Asia Limited [Member]
Subsidiary, Sale of Stock [Line Items]
Number of common shares callable by warrants	10,909		10,909